The following transactions are representative of my legal experience:

Carraro SpA: advising Carraro on its licensing of vehicle transmission technology from Torotrak

The Carlyle Group: advising Carlyle on the IP aspects of its £230 million acquisition of Britax Childcare (a leading UK manufacturer of premium branded safety seats for children)

The Co-operative Bank: advising the holders of lower tier 2 bonds issued by The Co-operative Bank plc on the IP aspects of the bank's £1.5 billion recapitalisation plan

Fairfax Financial Holdings Limited: advising Fairfax on the IP aspects of its £94 million acquisition of Thomas Cook Group plc's entire 77% stake in its Indian operations

Ford Motor Company: advising Ford on certain separation agreements which were ancillary to its $2.3 billion sale of the Jaguar and Land Rover operations to Tata Motors

Gallaher Group plc: advising Gallaher on the IP aspects of its joint venture with R. J. Reynolds for the manufacture and marketing of a portfolio of American blend cigarettes

Gemstar TV-Guide International, Inc.: advising Gemstar on its content licence agreement with BBC Worldwide for the provision of TV listings, editorial and advertising content for display with Gemstar's Guide-Plus electronic programme guide

Interbrew (now InBev): advising Interbrew on the IP aspects of its £2.3 billion acquisition of the brewing business of Bass (now Six Continents), its £400 million acquisition of the brewing business of Whitbread, and its subsequent £1.2 billion disposal of the Carling business to Coors

Ministry of Defence: advising the MoD on the IP aspects of vesting certain assets from the Defence Evaluation and Research Agency (DERA) into the government owned company QinetiQ, and the subsequent sale of a £150 million strategic stake in QinetiQ to The Carlyle Group

Mobile Telesystems OJSC: advising MTS on its exclusive strategic partnership with NTT DoCoMo for launch of the i-mode mobile phone service in Russia and other CIS countries

Shire plc: advising Shire on the IP aspects of its purchase of UCB's worldwide rights to Equasym for the treatment of ADHD